跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
連結會在新分頁中打開
English
中文
在 臺北醫學大學 搜尋內容
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
查看斯高帕斯 (Scopus) 概要
張 雅惠
副教授
,
臨床藥學學科
成員
,
臺北醫學大學胸腔醫學研究中心
https://orcid.org/0000-0002-1906-2274
電子郵件
elizabeth
tmu.edu
tw
h-index
212
引文
9
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2010
2026
每年研究成果
概覽
指紋
網路
專案
(21)
研究成果
(21)
類似的個人檔案
(8)
指紋
查看啟用 Elizabeth H. Chang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Nursing and Health Professions
Economic and Social Development
100%
Adherence
41%
Pilot Study
34%
Health Literacy
30%
Malignant Neoplasm
27%
Diseases
25%
Self Evaluation
23%
Psychometry
20%
Cronbach Alpha Coefficient
20%
Medication Compliance
16%
Epidermal Growth Factor Receptor Kinase Inhibitor
16%
Patient with Type 2 Diabetes
16%
Oral Antidiabetic Agent
16%
Non Small Cell Lung Cancer
16%
Parkinson's Disease
16%
Maturity Onset Diabetes of the Young
16%
Qualitative Research
16%
Anesthesist
16%
Health Promotion
16%
Cancer Pain Management
16%
Qualitative Study
16%
Patient Care
16%
Analgesia
16%
Professional Development
16%
Community Pharmacist
16%
Health Care Personnel
15%
Thematic Analysis
13%
Construct Validity
11%
Quality of Life
11%
Medicare
11%
Internal Consistency
10%
Caregiver Burden
10%
Blood Pressure
8%
Higher Education
8%
Prescription Drug
8%
Non Prescription Drug
8%
Study Participant
8%
Internal Validity
8%
Medication Error
8%
Content Validity
8%
Health Care
8%
Practice Experience
8%
Alzheimer's Disease
6%
Checklist
6%
Visual Analog Scale
6%
Hospital Department
5%
Terminal Disease
5%
Social Network
5%
Opioid
5%
Clinical Decision Making
5%
Pharmacology, Toxicology and Pharmaceutical Science
Community Pharmacy
50%
Clinical Pharmacy
33%
Hospital Pharmacy
19%
Chronic Kidney Failure
16%
Randomized Controlled Trial
16%
Overexertion
16%
Alzheimer's Disease
16%
Cohort Study
16%
Chronic Obstructive Lung Disease
16%
End Stage Renal Disease
12%
Drug-Drug Interaction
8%
Cholinesterase Inhibitor
8%
Diseases
8%
Medicine and Dentistry
Randomized Controlled Trial
16%
Network Meta-Analysis
16%
Patient with Type 2 Diabetes
16%
Cancer Pain Management
16%
Maturity Onset Diabetes of the Young
16%
Oncology
16%
Oral Antidiabetic Agent
16%
Chronic Kidney Disease
16%
Analgesia
16%
End Stage Renal Disease
12%
Malignant Neoplasm
11%
